February 29, 2008 -
Nippon Shinyaku Co., Ltd. and
Actelion Ltd announced today that the two companies have signed a binding letter of intent regarding Nippon Shinyaku's novel PGI 2 receptor agonist NS-304 for the treatment of pulmonary arterial hypertension (PAH) *1).
NS-304, originally discovered and synthesized by Nippon Shinyaku, is an orally available long acting prostaglandin I 2 receptor agonist *2) , w hich stim ulates PGI 2 receptor in blood vessels and exerts vasodilating effects. NS-304 has major potential as a novel treatment of PAH. Nippon Shinyaku has recently completed phase I evaluation in the United Kingdom. A phase II program in PAH patients was initiated in Europe at the end of 2007...
Nippon Shinyaku's Press Release -
Actelion's Press Release -
